21 citations,
May 2021 in “Prostate Cancer and Prostatic Diseases” COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.
34 citations,
September 2020 in “BMC Endocrine Disorders” Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.
2 citations,
August 2014 in “PubMed” Losartan may help treat Postural Orthostatic Tachycardia Syndrome (POTS) symptoms.
6 citations,
December 2022 in “Journal of Infection” The ACE1 gene variant doesn't affect long-COVID symptoms.
3 citations,
March 2022 in “Annals of Medicine” Hair shedding after COVID-19 is more linked to the disease's severity and inflammation rather than hormones, with women at higher risk.
1 citations,
May 2021 in “International Journal Of Medical Science And Clinical Invention” Women with PCOS may have a higher risk of severe COVID-19 due to hormonal imbalances and vitamin D deficiency.
19 citations,
December 2021 in “Cureus” Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.
18 citations,
October 2020 in “Radiation Research” Some drugs may help treat both COVID-19 and radiation injury.
5 citations,
December 2021 in “Scientific Reports” Age affects how certain proteins involved in COVID-19 infection are expressed in mice, but sex hormones and heart injury do not.
7 citations,
January 2021 in “The journal of gene medicine” Certain genetic differences may affect how likely someone is to get COVID-19 and how severe it might be.
4 citations,
April 2022 in “Dermatologic Therapy” Injecting scalp tissue micrografts is a safe and effective treatment for hair loss after COVID-19.
14 citations,
July 2021 in “Reviews in endocrine and metabolic disorders” SARS-CoV-2, the virus causing COVID-19, can affect all endocrine organs and systems, altering their function and potentially leading to disorders. Factors like diabetes and obesity increase infection risk and severity. Understanding these effects is key for effective treatment.
6 citations,
March 2022 in “Frontiers in drug discovery” Some small molecule antivirals show promise against COVID-19, but more research is needed to understand and improve them.
84 citations,
March 2010 in “Infectious Disease Clinics of North America” The document concludes that rapid identification, isolation, and strict infection control are crucial to manage SARS outbreaks.
9 citations,
March 2021 in “Hormones” COVID-19 may affect male fertility and women might have better outcomes due to hormonal and immune differences.
6 citations,
May 2021 in “Clinical Chemistry and Laboratory Medicine” Different ACE2 gene versions may affect COVID-19 impact based on age and suggest some hair loss drugs could be potential treatments.
121 citations,
November 2020 in “Endocrine” Male hormones like testosterone may make COVID-19 worse, and testing for sensitivity to these hormones could help predict how severe a patient's symptoms might be. Treatments that reduce these hormones are being explored.
4 citations,
June 2022 in “BioMed Research International” Using mesenchymal stem cells or their exosomes is safe for COVID-19 patients and helps improve lung healing and oxygen levels.
11 citations,
May 2021 in “Journal of Medical Virology” Men are more likely to have severe respiratory viral infections like COVID-19 due to hormonal and genetic differences, while women generally have stronger immune responses.
16 citations,
December 2021 in “Frontiers in Endocrinology” Sex hormones may affect COVID-19 severity, with estrogen possibly reducing risk and testosterone potentially increasing it.
176 citations,
May 2020 in “Dermatologic Therapy” COVID-19 can cause different skin symptoms that may help with early diagnosis and show how severe the disease is.
18 citations,
April 2021 in “Experimental Dermatology” COVID-19 may cause hair loss and scalp pain due to inflammation and changes in hair follicle receptors, but these symptoms typically resolve in 2 to 4 months.
September 2022 in “Frontiers in Immunology” Anti-androgen therapy may boost immunity but increases injection site pain in vaccinated patients.
70 citations,
July 2020 in “Pharmacological Reports” Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.
36 citations,
July 2020 in “Frontiers in Medicine” Spironolactone might help protect against severe lung problems in COVID-19 patients.
December 2022 in “Journal of Education, Health and Sport” Covid-19 can cause different types of hair loss, which can affect people's mental and social well-being.
July 2021 in “Journal of dermatology research and therapy” COVID-19 may worsen hair loss, and Nourkrin® could be a safe treatment option, but more research is needed.
1 citations,
April 2021 in “International Journal of Dermatology” Women with conditions like PCOS may have a higher risk of COVID-19, but treatments like isotretinoin could help those with acne.
2 citations,
September 2021 The COVID-19 pandemic increased the use of teledermatology to treat skin conditions in low-income areas, despite challenges like poor photo quality.
February 2022 in “International journal of KIU” Certain genes and nutrients like vitamin D, zinc, and omega fatty acids affect COVID-19 severity and infection risk.